CAM
PRME icon

Cormorant Asset Management’s Prime Medicine PRME Stock Holding History

Cormorant Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-734,350
Closed -$9.03M – 73
2023
Q1 		$9.03M Hold
734,350
– – 0.59% 41
2022
Q4 		$13.6M Buy
+734,350
New +$13.3M 0.91% 33

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Cormorant Asset Management's PRME Position: Q2 2023 in Review

Cormorant Asset Management sold out of Prime Medicine (PRME) in Q2 2023, closing a stake of 734,350 shares — an estimated $9.03M sold.

Cormorant Asset Management first reported a position in PRME in Q4 2022 and held it in 2 quarters. The position peaked at $13.6M in Q4 2022. 79 funds tracked by Wall St. Rank hold PRME as of Q2 2023.

  • Cormorant Asset Management reported no remaining Prime Medicine position as of Q2 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 734,350 Prime Medicine shares in Q2 2023, an estimated $9.03M.
  • Cormorant Asset Management first reported a position in Prime Medicine in Q4 2022 and held it in 2 quarters.
  • Cormorant Asset Management's Prime Medicine position peaked at $13.6M in Q4 2022.
  • 79 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.